A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Disease (protocol number ABE4869g)
What is the purpose of this trial?
The purpose of this study is to find out the safety and the effects, good and/or bad, of MABT5102A. The study is intended to find out what effects MABT5102A has on you and on Alzheimer’s disease. This study will also test different routes of administration (ways of giving the drug – either into your vein or under your skin).
- 50 Years - 80 Years
- Genentech, Inc.
- September 2011 - 2016
- Last Updated:
- Study HIC#: